Prostate CancerPRISON-UKNCT07870707
Prostate Cancer in UK Prisons: A Retrospective Data Analysis
An observational study of Prostate Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early stage. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- How many people
- 9,007 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 3 Dec 2026to 3 Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Study population: Men diagnosed with prostate cancer while in the care of His Majesty's Prison Service, are less likely to be diagnosed from screening and more likely to be diagnosed with late-stage disease, compared to that in the general population. In addition they are at risk of less favourable outcomes in terms of curative treatment and survival, compared to the general population.
Who may be able to join
- Pseudo-anonymous data from prostate cancer code-search in the digital health records of:
- Adult men (over 18 years of age) and people with prostates in the UK prison population with healthcare under Oxleas NHS Trust (sample includes 13 prisons under Oxleas NHS Trust with 9,007 adult men).
- Full data extraction will only occur for prisoners who have been diagnosed with prostate cancer while in the custody of His Majesty's Prison Service. The number of prisoners living with a diagnosis of prostate cancer will be noted, but no further data extraction will take place if diagnosed outside of prison.
- Prostate cancer diagnosis may be made clinically (based on symptoms, PSA levels and clinical examination) or confirmed with histology. Core data that ideally should be available for inclusion are:
- age at diagnosis
- method of diagnosis (screening/ 2WR (symptomatic)/ emergency),
Show all 10Show fewer
- PSA at diagnosis
- prostate cancer stage at diagnosis.
- The prisoners may or may not have another primary cancer at time of diagnosis, however the prostate cancer itself must also be a prostate primary.
- Records will be searched as far back as the Oxleas Data Team will be able to search electronic health records.
Who cannot join
- Although the number of prisoners living with a diagnosis of prostate cancer will be noted, those who were diagnosed with prostate cancer outside of their prison stay will not undergo further data extraction for data around diagnosis and outcomes.
- Potential participants who have opted out via the NHS England National Data Opt-Out (NDOO) service and therefore their data will not be used.
- Individual cases will be excluded if it is found that a diagnosis of prostate cancer was not received, even if they underwent extensive investigations for prostate cancer.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT
Dr Rose Hall, +44 (0)20 8722 4483, rose.hall@icr.ac.uk
Dr Joanne Droney, 02078082761, joanne.droney@rmh.nhs.uk
About this study
Official title: Prostate Cancer Retrospective Prevalence, Screening, Outcome Data in NHS-served Prisons UK (PRISON-UK)
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early stage. However, people in prison face significant barriers to healthcare, and little is known about how prostate cancer affects this population. This is concerning, as the prison population is ageing, and men over 50 are at the highest risk of developing prostate cancer. Research shows that prisoners are more likely to be diagnosed with any cancer at a late stage, often through emergency hospital visits, and are less likely to receive timely or curative treatment compared to the general population. Survival rates are also worse. However, there are very little data from the UK describing prostate cancer diagnosis and outcomes in the UK from the prison population, which this study aims to address and compare to a non-prison control group. This project, a collaboration between Oxleas NHS Trust and The Royal Marsden, will test and develop processes for extracting pseudo-anonymised data from the prison population. Using pseudo-anonymous data from prisoner health records in Oxleas NHS Trust, the Research Team will assess prevalence and examine how prostate cancer is diagnosed, the treatments offered, and the survival outcomes. Comparison will be made between the prison findings against UK Genetic Prostate Cancer Study (UKGPCS) data about men of a similar age in the non-prison population. Our aim is to understand whether prisoners face delays in diagnosis and worse outcomes, and to assess whether prison-based screening could help. The findings will inform future healthcare research and the development of policies and may support the development of tailored educational resources and screening approaches, ultimately helping to reduce health inequalities and improve outcomes for people in prison.
Read the detailed description
This study aims to test and develop data collection processes for SystmOne electronic healthcare records at Oxleas NHS Foundation Trust. To use these data collection methods to determine how many people are living with prostate cancer in prison, how prisoners are diagnosed with prostate cancer while in prison, whether they are diagnosed with early or late-stage disease and what are their treatment and survival outcomes. All cases of individuals living with prostate cancer in the Oxleas prison population will be noted. Data will be collected to investigate the parameters below for those diagnosed with prostate cancer during their time (on remand or sentenced) in the Oxleas prison population, as far back as electronic health records allow:
Age at diagnosis, Symptomatic at diagnosis, Mode of detection (emergency admission, GP/primary care, PSA screening), PSA at diagnosis, Prostate cancer stage at diagnosis (TMN), Gleason score at diagnosis, MDT treatment recommendation (curative or non-curative), Treatment modality offered at MDT (AS, RT, Surgery, SACT [Chemo, Hormone therapy, immunotherapy], palliative/ best supportive care, no treatment, other), Treatment modality received by patient (AS, RT, Surgery, SACT [Chemo, Hormone Hormone therapy, immunotherapy], palliative/ best supportive care, no treatment, other), Time until progression (in five-year age bands of year of diagnosis to cover things like reclassification and change in treatment regimens), Five-year survival, Cause of death.
Markers of poor access to cancer screening will also be assessed, such as delayed diagnosis and aggressive disease, such as: Pathology (prostate cancer grade and histology at diagnosis), Time elapsed from date referral received to date patient notified of diagnosis (NG12 suspected cancer pathway referral states this should be within 28 days(18)), Time elapsed from referral and receiving first treatment, Number of appointments cancelled or marked 'Did Not Attend'.
These data will provide novel evidence regarding prostate cancer diagnosis and treatment in prisoners under the care of NHS prisons.
Phase Two; How do the prevalence, PSA at diagnosis, method of diagnosis and treatment outcomes for men diagnosed with prostate cancer while in prison compare to that in the general population? To assess this, the data sets from Phase One will be compared with a general population group, using data from the UK Genetic Prostate Cancer Study (UKGPCS) to represent general population data, which will allow us to adjust for age and ethnicity as appropriate. The UKGPCS was established in 1993 and is the largest prostate cancer study in the UK, with data from 16,000 prostate cancer patients. The study is based with this same research team at the Institute of Cancer Research (ICR) and The Royal Marsden Hospital (RMH). Participants in UKGPCS are patients diagnosed with prostate cancer and who have consented to genetic testing and the storage of data detailing their diagnosis (including the above parameters extracted from the Oxleas prison population) and the future use of their data by the ICR research team. The control group will be the systematic series collection of data from the UKGPCS data set. One limitation of this study is that the UKGPCS dataset may include self-selection bias, as well as not being representative of the general population in terms of area and ethnicity.
- Conditions
- Prostate Cancer
- Keywords
- Prisoner health, Prostate cancer early diagnosis, Prostate cancer screening
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| N/A data collection of pre-existing data from 9007 adult male prisoners | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence, method of diagnosis, stage at diagnosis, outcomes of prostate cancer in the Oxleas NHS prison population
Prevalence statistics from the number of adult men and people with prostates in the prison population under Oxleas NHS Foundation Trust, who are identified as living with a diagnosis of prostate cancer. For those who received the diagnosis in prison, data will be collected form their electronic health record to include PSA at diagnosis, method of diagnosis (diagnosed through PSA screening, symptomatic presentation via primary care/2-week-wait referral, emergency presentation), stage and grade at diagnosis and time intervals between referral and diagnosis and treatment received.
Measured: Electronic health records will be searched from the earliest available to completion of data extraction, anticipated 31 July 2027. Data collection will occur between January 2027 and July 2027.
Secondary outcomes (1)
How does the primary outcome data compare to the general population included in the UKGPCS dataset
Comparison between prostate cancer diagnosis, treatment and outcome data collected from the prison population with age and ethnicity matched individuals in the general population from the UKGPCS dataset, using statistical analysis to present findings.
Measured: Comparison between data sets and statistical analysis will occur in July and August 2027.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study start3 Dec 2026 (estimated)
- Primary completion3 Aug 2027 (estimated)
- Study completion3 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Royal Marsden NHS Foundation TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 9,007 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Public Health England, The Institute of Cancer Research, Sutton, Surrey, UK
- Responsible party
- Sponsor
- Investigators
- Dr Elizabeth Bancroft, Principal investigator, Royal Marsden NHS Foundation TrustDr Rose Hall, Study chair, Institute of Cancer Research, United Kingdom
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07870707
- Sponsor's protocol ID
- CCR6325
- Acronym
- PRISON-UK
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Brook MN, Ni Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol. 2023 Mar;83(3):257-266. doi: 10.1016/j.eururo.2022.11.019. Epub 2022 Dec 16.
PubMed 36528478Jager M, de Zeeuw J, Tullius J, Papa R, Giammarchi C, Whittal A, de Winter AF. Patient Perspectives to Inform a Health Literacy Educational Program: A Systematic Review and Thematic Synthesis of Qualitative Studies. Int J Environ Res Public Health. 2019 Nov 5;16(21):4300. doi: 10.3390/ijerph16214300.
PubMed 31694299Kouyoumdjian FG, Kiefer L, Wobeser W, Gonzalez A, Hwang SW. Mortality over 12 years of follow-up in people admitted to provincial custody in Ontario: a retrospective cohort study. CMAJ Open. 2016 Apr 27;4(2):E153-61. doi: 10.9778/cmajo.20150098. eCollection 2016 Apr-Jun.
PubMed 27398358Bellass S, Canvin K, Farragher T, McLintock K, Wright N, Hearty P, Seanor N, Cunningham M, Foy R, Sheard L. Understanding and improving the quality of primary care for people in prison: a mixed-methods study. Health Soc Care Deliv Res. 2024 Nov;12(46):1-329. doi: 10.3310/GRFV4068.
PubMed 39514203Armes J, Visser R, Luchtenborg M, Huynh J, Wheatcroft S, X A, Barber AE, Plugge E, Taylor RM, Hunter RM, Davies EA. Cancer in prison: barriers and enablers to diagnosis and treatment. EClinicalMedicine. 2024 Apr 29;72:102540. doi: 10.1016/j.eclinm.2024.102540. eCollection 2024 Jun.
PubMed 39010978Aziz H, Ackah RL, Whitson A, Oppong B, Obeng-Gyasi S, Sims C, Pawlik TM. Cancer Care in the Incarcerated Population: Barriers to Quality Care and Opportunities for Improvement. JAMA Surg. 2021 Oct 1;156(10):964-973. doi: 10.1001/jamasurg.2021.3754.
PubMed 34406357Organisation WH. Cancer and cardiovascular health inequities in prison settings: a rapid literature review2022 25 aug 2026. Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2022-5814-45579-65357.
UK CR. Prostate Cancer Statistics2023 22/08/2023. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer.
Justice Mo. Safety in custody: quarterly update to September 20252026 25 Aug 2026. Available from: https://www.gov.uk/government/statistics/safety-in-custody-quarterly-update-to-september-2025.
Ombudsman PaP. Learning from PPO investigations: Natural cause deaths in prison custody 2007-2010 2012 25 Aug 2026. Available from: https://cdn.websitebuilder.service.justice.gov.uk/uploads/sites/14/2024/07/learning_from_ppo_investigations-natural_cause_deaths_in_prison_custody.pdf.
Justice Mo. Safety in Custody Statistics, England and Wales: Deaths in Prison Custody to December 2025 Self-harm and Assaults to September 2025. In: Justice Mo, editor. 2026.
Ombudsman PaP. Prisons and Probation Ombudsman Annual Report 2024 to 2025. In: Justice Mo, editor. 2026.
Library HoC. Prison Population Statistics. In: Briefing HoCLR, editor. 2026.
England PH. Health and Justice Annual Review2019 15/01/2025. Available from: https://assets.publishing.service.gov.uk/media/5d2ef3f840f0b64a7fa8b374/Public_Health_England_Health_and_Justice_Annual_Review_2018-2019.pdf.
Luchtenborg M, Huynh J, Armes J, Plugge E, Hunter RM, Visser R, Taylor RM, Davies EA. Cancer incidence, treatment, and survival in the prison population compared with the general population in England: a population-based, matched cohort study. Lancet Oncol. 2024 May;25(5):553-562. doi: 10.1016/S1470-2045(24)00035-4.
PubMed 38697154
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prostate Cancer Retrospective Prevalence, Screening, Outcome Data in NHS-served Prisons UK (PRISON-UK)
- ClinicalTrials.gov ID
- NCT07870707
- Acronym / sponsor ID
- PRISON-UK / CCR6325
- Conditions
- Prostate Cancer
- Keywords
- Prisoner health, Prostate cancer early diagnosis, Prostate cancer screening
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 9,007 participants (estimated)
- Lead sponsor
- Royal Marsden NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Public Health England, The Institute of Cancer Research, Sutton, Surrey, UK
- Study start
- 3 Dec 2026 (estimated)
- Primary completion
- 3 Aug 2027 (estimated)
- Study completion
- 3 Aug 2028 (estimated)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prostate cancer is the most common cancer affecting men in the United Kingdom (UK) and is the most common cancer in UK prisons. Early diagnosis is vital because treatment is more effective when the disease is detected at an early stage. However, people in prison face significant barriers to healthcare, and little is known about how prostate cancer affects this population. This is concerning, as the prison population is ageing, and men over 50 are at the highest risk of developing prostate cancer. Research shows that prisoners are more likely to be diagnosed with any cancer at a late stage, often through emergency hospital visits, and are less likely to receive timely or curative treatment compared to the general population. Survival rates are also worse. However, there are very little data from the UK describing prostate cancer diagnosis and outcomes in the UK from the prison population, which this study aims to address and compare to a non-prison control group. This project, a collaboration between Oxleas NHS Trust and The Royal Marsden, will test and develop processes for extracting pseudo-anonymised data from the prison population. Using pseudo-anonymous data from prisoner health records in Oxleas NHS Trust, the Research Team will assess prevalence and examine how prostate cancer is diagnosed, the treatments offered, and the survival outcomes. Comparison will be made between the prison findings against UK Genetic Prostate Cancer Study (UKGPCS) data about men of a similar age in the non-prison population. Our aim is to understand whether prisoners face delays in diagnosis and worse outcomes, and to assess whether prison-based screening could help. The findings will inform future healthcare research and the development of policies and may support the development of tailored educational resources and screening approaches, ultimately helping to reduce health inequalities and improve outcomes for people in prison.
Detailed description
This study aims to test and develop data collection processes for SystmOne electronic healthcare records at Oxleas NHS Foundation Trust. To use these data collection methods to determine how many people are living with prostate cancer in prison, how prisoners are diagnosed with prostate cancer while in prison, whether they are diagnosed with early or late-stage disease and what are their treatment and survival outcomes. All cases of individuals living with prostate cancer in the Oxleas prison population will be noted. Data will be collected to investigate the parameters below for those diagnosed with prostate cancer during their time (on remand or sentenced) in the Oxleas prison population, as far back as electronic health records allow:
Age at diagnosis, Symptomatic at diagnosis, Mode of detection (emergency admission, GP/primary care, PSA screening), PSA at diagnosis, Prostate cancer stage at diagnosis (TMN), Gleason score at diagnosis, MDT treatment recommendation (curative or non-curative), Treatment modality offered at MDT (AS, RT, Surgery, SACT [Chemo, Hormone therapy, immunotherapy], palliative/ best supportive care, no treatment, other), Treatment modality received by patient (AS, RT, Surgery, SACT [Chemo, Hormone Hormone therapy, immunotherapy], palliative/ best supportive care, no treatment, other), Time until progression (in five-year age bands of year of diagnosis to cover things like reclassification and change in treatment regimens), Five-year survival, Cause of death.
Markers of poor access to cancer screening will also be assessed, such as delayed diagnosis and aggressive disease, such as: Pathology (prostate cancer grade and histology at diagnosis), Time elapsed from date referral received to date patient notified of diagnosis (NG12 suspected cancer pathway referral states this should be within 28 days(18)), Time elapsed from referral and receiving first treatment, Number of appointments cancelled or marked 'Did Not Attend'.
These data will provide novel evidence regarding prostate cancer diagnosis and treatment in prisoners under the care of NHS prisons.
Phase Two; How do the prevalence, PSA at diagnosis, method of diagnosis and treatment outcomes for men diagnosed with prostate cancer while in prison compare to that in the general population? To assess this, the data sets from Phase One will be compared with a general population group, using data from the UK Genetic Prostate Cancer Study (UKGPCS) to represent general population data, which will allow us to adjust for age and ethnicity as appropriate. The UKGPCS was established in 1993 and is the largest prostate cancer study in the UK, with data from 16,000 prostate cancer patients. The study is based with this same research team at the Institute of Cancer Research (ICR) and The Royal Marsden Hospital (RMH). Participants in UKGPCS are patients diagnosed with prostate cancer and who have consented to genetic testing and the storage of data detailing their diagnosis (including the above parameters extracted from the Oxleas prison population) and the future use of their data by the ICR research team. The control group will be the systematic series collection of data from the UKGPCS data set. One limitation of this study is that the UKGPCS dataset may include self-selection bias, as well as not being representative of the general population in terms of area and ethnicity.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| N/A data collection of pre-existing data from 9007 adult male prisoners | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Men diagnosed with prostate cancer while in the care of His Majesty's Prison Service, are less likely to be diagnosed from screening and more likely to be diagnosed with late-stage disease, compared to that in the general population. In addition they are at risk of less favourable outcomes in terms of curative treatment and survival, compared to the general population.
Key inclusion criteria (10 listed)
- Adult men (over 18 years of age) and people with prostates in the UK prison population with healthcare under Oxleas NHS Trust (sample includes 13 prisons under Oxleas NHS Trust with 9,007 adult men).
- Full data extraction will only occur for prisoners who have been diagnosed with prostate cancer while in the custody of His Majesty's Prison Service. The number of prisoners living with a diagnosis of prostate cancer will be noted, but no further data extraction will take place if diagnosed outside of prison.
- Prostate cancer diagnosis may be made clinically (based on symptoms, PSA levels and clinical examination) or confirmed with histology. Core data that ideally should be available for inclusion are:
- The prisoners may or may not have another primary cancer at time of diagnosis, however the prostate cancer itself must also be a prostate primary.
- Records will be searched as far back as the Oxleas Data Team will be able to search electronic health records.
Key exclusion criteria (3 listed)
- Although the number of prisoners living with a diagnosis of prostate cancer will be noted, those who were diagnosed with prostate cancer outside of their prison stay will not undergo further data extraction for data around diagnosis and outcomes.
- Potential participants who have opted out via the NHS England National Data Opt-Out (NDOO) service and therefore their data will not be used.
- Individual cases will be excluded if it is found that a diagnosis of prostate cancer was not received, even if they underwent extensive investigations for prostate cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence, method of diagnosis, stage at diagnosis, outcomes of prostate cancer in the Oxleas NHS prison population
Time frame: Electronic health records will be searched from the earliest available to completion of data extraction, anticipated 31 July 2027. Data collection will occur between January 2027 and July 2027.
Prevalence statistics from the number of adult men and people with prostates in the prison population under Oxleas NHS Foundation Trust, who are identified as living with a diagnosis of prostate cancer. For those who received the diagnosis in prison, data will be collected form their electronic health record to include PSA at diagnosis, method of diagnosis (diagnosed through PSA screening, symptomatic presentation via primary care/2-week-wait referral, emergency presentation), stage and grade at diagnosis and time intervals between referral and diagnosis and treatment received.
1 secondary outcome
How does the primary outcome data compare to the general population included in the UKGPCS dataset
Time frame: Comparison between data sets and statistical analysis will occur in July and August 2027.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Background: PubMed 36528478Brook MN, Ni Raghallaigh H, Govindasami K, Dadaev T, Rageevakumar R, Keating D, Hussain N, Osborne A, Lophatananon A; UKGPCS Collaborators; Muir KR, Kote-Jarai Z, Eeles RA. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol. 2023 Mar;83(3):257-266. doi: 10.1016/j.eururo.2022.11.019. Epub 2022 Dec 16.
- Background: PubMed 31694299Jager M, de Zeeuw J, Tullius J, Papa R, Giammarchi C, Whittal A, de Winter AF. Patient Perspectives to Inform a Health Literacy Educational Program: A Systematic Review and Thematic Synthesis of Qualitative Studies. Int J Environ Res Public Health. 2019 Nov 5;16(21):4300. doi: 10.3390/ijerph16214300.
- Background: PubMed 27398358Kouyoumdjian FG, Kiefer L, Wobeser W, Gonzalez A, Hwang SW. Mortality over 12 years of follow-up in people admitted to provincial custody in Ontario: a retrospective cohort study. CMAJ Open. 2016 Apr 27;4(2):E153-61. doi: 10.9778/cmajo.20150098. eCollection 2016 Apr-Jun.
- Background: PubMed 39514203Bellass S, Canvin K, Farragher T, McLintock K, Wright N, Hearty P, Seanor N, Cunningham M, Foy R, Sheard L. Understanding and improving the quality of primary care for people in prison: a mixed-methods study. Health Soc Care Deliv Res. 2024 Nov;12(46):1-329. doi: 10.3310/GRFV4068.
- Background: PubMed 39010978Armes J, Visser R, Luchtenborg M, Huynh J, Wheatcroft S, X A, Barber AE, Plugge E, Taylor RM, Hunter RM, Davies EA. Cancer in prison: barriers and enablers to diagnosis and treatment. EClinicalMedicine. 2024 Apr 29;72:102540. doi: 10.1016/j.eclinm.2024.102540. eCollection 2024 Jun.
- Background: PubMed 34406357Aziz H, Ackah RL, Whitson A, Oppong B, Obeng-Gyasi S, Sims C, Pawlik TM. Cancer Care in the Incarcerated Population: Barriers to Quality Care and Opportunities for Improvement. JAMA Surg. 2021 Oct 1;156(10):964-973. doi: 10.1001/jamasurg.2021.3754.
- BackgroundOrganisation WH. Cancer and cardiovascular health inequities in prison settings: a rapid literature review2022 25 aug 2026. Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2022-5814-45579-65357.
- BackgroundUK CR. Prostate Cancer Statistics2023 22/08/2023. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer.
- BackgroundJustice Mo. Safety in custody: quarterly update to September 20252026 25 Aug 2026. Available from: https://www.gov.uk/government/statistics/safety-in-custody-quarterly-update-to-september-2025.
- BackgroundOmbudsman PaP. Learning from PPO investigations: Natural cause deaths in prison custody 2007-2010 2012 25 Aug 2026. Available from: https://cdn.websitebuilder.service.justice.gov.uk/uploads/sites/14/2024/07/learning_from_ppo_investigations-natural_cause_deaths_in_prison_custody.pdf.
- BackgroundJustice Mo. Safety in Custody Statistics, England and Wales: Deaths in Prison Custody to December 2025 Self-harm and Assaults to September 2025. In: Justice Mo, editor. 2026.
- BackgroundOmbudsman PaP. Prisons and Probation Ombudsman Annual Report 2024 to 2025. In: Justice Mo, editor. 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Prostate Cancer
Active, not recruitingPhase 2/3
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Prostate Cancer, Oligometastasis
Not yet recruiting
Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal Cancer
Breast Cancer Stage I, Colorectal Cancer
RecruitingPhase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Active, not recruitingObservational study
Spatial Needle Placement Strategies and Pathological Concordance in Prostate Biopsy: A National Multicenter Retrospective Cohort Study
Prostate Cancer, Prostatic Neoplasms
Active, not recruitingPhase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dr Elizabeth Bancroft principal investigator
Royal Marsden NHS Foundation Trust
Dr Rose Hall study chair
Institute of Cancer Research, United Kingdom
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prostate Cancer, run by Royal Marsden NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr Rose Hall (+44 (0)20 8722 4483, rose.hall@icr.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence, method of diagnosis, stage at diagnosis, outcomes of prostate cancer in the Oxleas NHS prison population (time frame: Electronic health records will be searched from the earliest available to completion of data extraction, anticipated 31 July 2027. Data collection will occur between January 2027 and July 2027.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07870707, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.